PGT-A Genetic Screening in Fertility Care
Genetic Screening (PGT-A) in Modern Fertility Care: Who Actually Needs It?
When a woman begins fertility treatment, the number of decisions can feel overwhelming. Should you try medicines first? Is IUI enough? When is IVF the right step? And if IVF is advised, should you also test embryos through PGT-A? Many patients hear about genetic screening and assume it is something every IVF cycle should include. In reality, PGT-A can be helpful in selected situations, but it is not a universal requirement for every woman or couple trying to conceive.
At ARC Fertility Hospitals, conversations around PGT-A are usually guided by one central question: will this test meaningfully improve decision-making for this patient? That distinction matters. A test can be scientifically advanced, but it should still be used thoughtfully, with clear counselling about benefits, limitations, emotional impact, and cost.
What Is PGT-A?
PGT-A stands for Preimplantation Genetic Testing for Aneuploidy. It is a test performed during an IVF cycle to check whether embryos have the expected number of chromosomes. Human embryos should usually have 46 chromosomes. If an embryo has missing or extra chromosomes, it may fail to implant, lead to miscarriage, or result in certain chromosomal conditions.
In a typical IVF cycle with PGT-A, eggs are collected, fertilised in the laboratory, and embryos are grown for a few days until they reach the blastocyst stage. A few cells are then carefully biopsied from the outer layer of the embryo, which later forms the placenta. These cells are sent for genetic analysis while the embryo is usually frozen. Once results are available, doctors can prioritise embryos that are chromosomally suitable for transfer.
It is important to understand what PGT-A does not do. It does not guarantee pregnancy. It does not check every possible genetic disease. It is different from PGT-M, which is used when there is a known single-gene disorder in the family. PGT-A mainly helps with chromosomal screening and embryo selection.
Why Chromosomes Matter in IVF
Many women blame themselves when an IVF cycle fails or when a pregnancy ends early. But in a significant number of cases, the reason is biological rather than behavioural. Embryos with chromosomal imbalance often look normal under the microscope, yet may not have the ability to continue developing.
This is one reason PGT-A became part of modern fertility care. It offers extra information beyond embryo appearance. However, more information is not always equal to better outcomes for everyone. The usefulness of PGT-A depends strongly on age, fertility history, embryo number, previous miscarriages, and the reason IVF is being done.
Who May Actually Benefit from PGT-A?
Women of advanced reproductive age
As women age, especially after 35, the proportion of eggs and embryos with chromosomal abnormalities tends to increase. This does not mean pregnancy is impossible, but embryo selection becomes more complex. For women in their late thirties or forties, PGT-A may help identify embryos with a better chromosomal profile, potentially reducing the chance of transferring embryos unlikely to implant.
Couples with recurrent pregnancy loss
Repeated miscarriage can be emotionally exhausting. When miscarriages are suspected to be linked to chromosomal abnormalities, PGT-A may be considered as part of a broader evaluation. It should not replace other investigations, such as uterine assessment, hormonal review, clotting-related evaluation when indicated, or parental karyotyping in selected cases. But it may help reduce uncertainty around embryo chromosomal status.
Repeated IVF failure despite good-looking embryos
Some patients have transferred embryos that appeared strong in the laboratory but did not implant. In such cases, doctors look at multiple possibilities: embryo genetics, uterine receptivity, sperm quality, stimulation response, endometrial factors, and medical conditions. PGT-A may be discussed when embryo chromosomal status is a likely missing piece in the picture.
Patients with many embryos and a need to prioritise transfer
In some IVF cycles, patients may have several blastocysts. Choosing which embryo to transfer first can become important, especially when time, emotional energy, or previous failed transfers are concerns. PGT-A may help rank embryos for transfer, though it still cannot predict implantation with certainty.
Who May Not Need PGT-A?
PGT-A is not automatically needed for every young woman undergoing IVF. If a woman is younger, has a good prognosis, no miscarriage history, and only a small number of embryos, the benefit may be limited. In some cases, testing may add cost and waiting time without clearly improving the chance of having a baby.
It may also be less useful when there are very few embryos available. If only one embryo forms, some patients may prefer transfer after counselling rather than testing, especially because PGT-A cannot improve the embryo itself. It can only provide information about chromosomal status based on sampled cells.
This is where personalised fertility counselling matters. A woman should not feel pressured into PGT-A simply because it sounds advanced. The better question is: will the result change the treatment plan?
PGT-A, IUI, and IVF: Where Does It Fit?
PGT-A can only be done as part of IVF because embryos must be created in the laboratory before testing. It cannot be done with IUI. For women deciding between IUI and IVF, doctors first consider age, fallopian tube status, sperm parameters, ovulation, duration of infertility, and previous treatment history.
For example, a younger woman with open tubes, mild ovulation issues, and a short duration of infertility may not need IVF immediately. IUI may be reasonable. But a woman over 38 with a long infertility history, low ovarian reserve, or previous miscarriages may be counselled differently. If IVF is chosen, PGT-A may then enter the discussion depending on the full clinical picture.
Cost and Time Considerations
PGT-A adds cost to an IVF cycle because it involves embryo biopsy, freezing, laboratory genetic testing, and later frozen embryo transfer planning. It may also extend the timeline because embryos are usually not transferred immediately in the same cycle. For many women, this waiting period can feel emotionally heavy, especially after already going through injections, scans, egg retrieval, and fertilisation updates.
Cost should be discussed openly before starting treatment. A responsible fertility team will explain whether PGT-A is strongly recommended, optional, or unlikely to add much value in your case. Patients should feel comfortable asking: Why am I being advised this test? What will we do differently based on the result? What are the alternatives if we do not test?
What Are the Limitations of PGT-A?
PGT-A is a screening test, not a promise. Embryos reported as suitable still may not implant. Embryos can also show mosaic results, meaning tested cells may contain a mixture of normal and abnormal chromosomal patterns. Mosaic embryo decisions require careful counselling and should not be reduced to a simple yes or no.
There is also the reality that PGT-A tests a small sample of cells from the embryo’s outer layer. Although technology has improved, interpretation still needs expertise. This is why embryo testing should always be paired with genetic counselling and fertility specialist guidance, not treated as a standalone shortcut.
How ARC Fertility Hospitals Approach the Decision
At ARC Fertility Hospitals, PGT-A is considered within the broader fertility journey, not as an isolated add-on. Doctors assess age, ovarian reserve, semen analysis, previous pregnancy history, embryo development, ultrasound findings, and emotional readiness. For women comparing centres and trying to understand advanced IVF options, speaking with specialists at the Best IVF centre in Hyderabad can help clarify whether embryo genetic screening is relevant to their situation.
The goal is not to test more embryos for the sake of technology. The goal is to make embryo transfer decisions more informed when the clinical situation justifies it.
Questions to Ask Before Saying Yes to PGT-A
Before choosing PGT-A, ask your fertility doctor a few practical questions. Is my age or fertility history a strong reason for testing? How many embryos are likely to reach the blastocyst stage? Will testing change which embryo is transferred first? What happens if all embryos are abnormal or mosaic? What are the costs, timelines, and emotional implications?
These questions are not signs of doubt. They are signs of informed participation. Fertility treatment often feels like handing your future to medical science, but good care should bring you into the decision-making process with clarity and respect.
The Bottom Line
PGT-A is a valuable tool in modern IVF, especially for women of advanced reproductive age, those with recurrent miscarriages, repeated IVF failure, or multiple embryos where selection is difficult. But it is not necessary for everyone. The right use of PGT-A depends on whether it can answer a meaningful clinical question in your treatment plan.
If you are considering IVF and feel confused about embryo testing, the most helpful next step is a personalised fertility evaluation. With the right explanation, PGT-A becomes less frightening and less mysterious. It becomes what it should be: one possible tool, used carefully, to support better fertility decisions.
0
52 min ago
- Whatsapp
- Facebook
- Linkedin
- Google Plus
1